Smartphones and Intelligent Socks to Help Prevent Diabetic Amputations

Diabetic neuropathy is a type of nerve damage associated with the development of foot ulcers in patients with diabetes. Resulting from anatomical deformation, excessive pressure and poor blood supply, it affects over 130 million individuals worldwide. It is also the leading cause of amputation, costing the United States economy alone more than $10 billion annually.

Diabetic patients are encouraged to get regular checkups to monitor for the increased pressure and ulceration that can eventually require amputation. However, ulcers are only diagnosed after they occur, meaning that patients require healing time, which dramatically increases healthcare costs.

Members of the BioDesign: Medical Innovation program, created by The Hebrew University of Jerusalem and its affiliated Hadassah Medical Center, set out to solve this problem.

"This is a significant medical problem that affects the lives of millions. We thought there must be a way to avoid these wounds altogether," said Danny Bavli, the group's lead engineer.

To address this challenge, Bavli partnered with Sagi Frishman and Dr. David Morgenstern, a leading orthopedic surgeon at Hadassah Medical Center. Together with other members of the Hebrew University BioDesign group, they developed SenseGO, a machine-washable sock containing dozens of micro-fabricated pressure sensors.

With SenseGO, changes in pressure due to incorrect posture, anatomical deformation or ill-fitting shoes are registered as electrical signals that are relayed to a smartphone app, which in turn informs the patient of developing risk.

Prof. Yaakov Nahmias, BioDesign program director, said: "This is a classic mobile health approach. By giving patients and their families the tools they need to prevent the development of ulcers, we can dramatically reduce health care costs related to diabetes."

Other members of the BioDesign SenseGO team included Inbal Boxerman and Yael Hadar, MBA students at The Hebrew University of Jerusalem.

BioDesign: Medical Innovation is a multi-disciplinary, team-based approach to medical innovation, created by the Hebrew University of Jerusalem and its affiliated Hadassah Medical Center. Sponsored by Boston Scientific and the Terumo Medical Corporation, the program takes outstanding medical fellows, bioengineering and business graduate students, and tutors them in the science and practice of bringing a medical innovation to the market. The program is directed by Prof. Yaakov Nahmias, director of the Alexander Grass Center for Bioengineering at the Hebrew University of Jerusalem, and Prof. Chaim Lotan, director of the Heart Institute at Hadassah Medical Center.

The innovations produced by the Biodesign program participants are commercialized by Yissum, the technology transfer company of the Hebrew University of Jerusalem, and Hadasit, the technology transfer company of the Hadassah Medical Center.

Most Popular Now

Information Integration and Artificial I…

With their joint research alliance, Siemens Healthineers and the Fraunhofer Institute for Medical Image Computing MEVIS will support physicians in finding the right course of therapy for their patients. Both...

Philips and Illumina Team Up with Navica…

Royal Philips (NYSE: PHG, AEX: PHIA) and Navican, an Intermountain Healthcare company, today signed an agreement to deploy a precision health informatics solution that will allow hospitals and health systems...

Mind-Controlled Device Helps Stroke Pati…

Stroke patients who learned to use their minds to open and close a device fitted over their paralyzed hands gained some control over their hands, according to a new study...

Zebra Announces Regulatory Approval of i…

Zebra Medical Vision, the leading machine learning imaging analytics company, announces that the company has been granted the CE approval and subsequent release of its Deep Learning Analytics Engine in...

Technology for Health

InterComponentWare AG (ICW) is a leading supplier of software for the healthcare IT market. ICW develops solutions for IT-based collaboration among healthcare professionals and their patients. ICW is your trusted...

Tablet Helps Heart Failure Patients Mana…

A novel tablet is helping heart failure patients to manage their disease including drug dosages, according to research presented at EuroHeartCare 2017.(1) Heart failure is a serious condition in which...

IBM Security Launches New Capabilities t…

IBM (NYSE: IBM) has announced new incident response capabilities, from its IBM Resilient security portfolio, to help companies address the new General Data Protection Regulation (GDPR). These capabilities are designed...

NHS Organisations to Access IMS MAXIMS C…

Award-winning electronic patient record (EPR) provider IMS MAXIMS has announced the availability of its cloud services on the latest iteration of the UK Government's G Cloud Framework. NHS organisations looking...

Boehringer Ingelheim Builds Digital Lab …

With the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot. The start-up will work closely together...

Anyone can Become More Curious. Is that …

Merck, a leading science and technology company, today announced the start of an experiment entitled "Anyone can become more curious". Driven by the company’s curiosity initiative, which measured and described...

Artificial Intelligence to Assist in the…

The University of Tampere and TAYS (Tampere University Hospital) Heart Hospital use artificial intelligence (A.I.) technologies developed by VTT Technical Research Centre of Finland in the home care of heart...

KLAS Report: InterSystems TrakCare Tops …

InterSystems' electronic medical record (EMR) technology has been deployed by more hospitals than any other vendor's software during the past four years, according to a research report published today by...